Haemonetics Corp (HAE) stock
HAENYSESurgical & Medical Instruments & ApparatusFiscal year ends April 3
Financials through Q2 FY2027, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3064% above fair value
$122.94+0.23 (+0.19%)
Close on Nov 13, 2026Market cap $5.59BP/E 54.9Yield –
Haemonetics r&d expenses
Research and development expenses are spending on new products and technology.
Haemonetics's R&D Expenses for the twelve months ending Sep 26, 2026 was $61.86M, down 5.2% year over year. For fiscal 2026 it was $59.77M, down 4.7% from the year before. Over ten years it grew 2.9% a year on average. The highest annual figure on record is $62.72M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 28, 2026 | $59.77M | -4.7% |
| FY2025 | Mar 29, 2025 | $62.72M | +15.2% |
| FY2024 | Mar 30, 2024 | $54.44M | +8.6% |
| FY2023 | Apr 1, 2023 | $50.13M | +7.1% |
| FY2022 | Apr 2, 2022 | $46.80M | +42.4% |
| FY2021 | Apr 3, 2021 | $32.86M | +6.4% |
| FY2020 | Mar 28, 2020 | $30.88M | -13.5% |
| FY2019 | Mar 30, 2019 | $35.71M | -9.0% |
| FY2018 | Mar 31, 2018 | $39.23M | +4.5% |
| FY2017 | Apr 1, 2017 | $37.56M | -16.5% |
| FY2016 | Apr 2, 2016 | $44.97M | -17.0% |
| FY2015 | Mar 28, 2015 | $54.19M | -0.0% |
| FY2014 | Mar 29, 2014 | $54.20M | +22.1% |
| FY2013 | Mar 30, 2013 | $44.39M | +20.6% |
| FY2012 | Mar 31, 2012 | $36.80M | +12.7% |
| FY2011 | Apr 2, 2011 | $32.66M | +23.8% |
| FY2010 | Apr 3, 2010 | $26.38M | +10.5% |
| FY2009 | Mar 28, 2009 | $23.86M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 26, 2026 | $17.03M | +14.5% |
| Q1 FY2027CQ2 2026 | Jun 27, 2026 | $16.20M | -0.4% |
| Q4 FY2026CQ1 2026 | Mar 28, 2026 | $14.45M | -21.1% |
| Q3 FY2026CQ4 2025 | Dec 27, 2025 | $14.19M | -10.4% |
| Q2 FY2026CQ3 2025 | Sep 27, 2025 | $14.87M | +5.2% |
| Q1 FY2026CQ2 2025 | Jun 28, 2025 | $16.26M | +12.5% |
| Q4 FY2025CQ1 2025 | Mar 29, 2025 | $18.31M | +15.4% |
| Q3 FY2025CQ4 2024 | Dec 28, 2024 | $15.83M | +19.3% |
| Q2 FY2025CQ3 2024 | Sep 28, 2024 | $14.14M | +11.6% |
| Q1 FY2025CQ2 2024 | Jun 29, 2024 | $14.45M | +14.2% |
| Q4 FY2024CQ1 2024 | Mar 30, 2024 | $15.86M | +1.4% |
| Q3 FY2024CQ4 2023 | Dec 30, 2023 | $13.27M | +4.5% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $12.67M | +16.2% |
| Q1 FY2024CQ2 2023 | Jul 1, 2023 | $12.65M | +16.0% |
| Q4 FY2023CQ1 2023 | Apr 1, 2023 | $15.64M | +18.4% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $12.69M | +26.4% |
| Q2 FY2023CQ3 2022 | Oct 1, 2022 | $10.90M | +0.4% |
| Q1 FY2023CQ2 2022 | Jul 2, 2022 | $10.90M | -14.2% |
| Q4 FY2022CQ1 2022 | Apr 2, 2022 | $13.21M | +21.8% |
| Q3 FY2022CQ4 2021 | Jan 1, 2022 | $10.04M | +33.8% |
| Q2 FY2022CQ3 2021 | Oct 2, 2021 | $10.85M | +60.5% |
| Q1 FY2022CQ2 2021 | Jul 3, 2021 | $12.70M | +63.9% |
| Q4 FY2021CQ1 2021 | Apr 3, 2021 | $10.84M | +20.8% |
| Q3 FY2021CQ4 2020 | Dec 26, 2020 | $7.50M | +7.2% |
| Q2 FY2021CQ3 2020 | Sep 26, 2020 | $6.76M | -8.9% |
| Q1 FY2021CQ2 2020 | Jun 27, 2020 | $7.75M | +3.5% |
| Q4 FY2020CQ1 2020 | Mar 28, 2020 | $8.97M | +2.6% |
| Q3 FY2020CQ4 2019 | Dec 28, 2019 | $7.00M | -22.0% |
| Q2 FY2020CQ3 2019 | Sep 28, 2019 | $7.42M | -13.5% |
| Q1 FY2020CQ2 2019 | Jun 29, 2019 | $7.49M | -20.4% |
| Q4 FY2019CQ1 2019 | Mar 30, 2019 | $8.75M | -21.1% |
| Q3 FY2019CQ4 2018 | Dec 29, 2018 | $8.98M | -27.8% |
| Q2 FY2019CQ3 2018 | Sep 29, 2018 | $8.58M | +14.1% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $9.41M | +14.8% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $11.09M | +18.9% |
| Q3 FY2018CQ4 2017 | Dec 30, 2017 | $12.43M | +46.9% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $7.52M | – |
| Q1 FY2018CQ2 2017 | Jul 1, 2017 | $8.19M | – |
| Q4 FY2017CQ1 2017 | Apr 1, 2017 | $9.32M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $8.46M | – |
See a number that looks wrong?